The Cancer Letter

Jacks said @break_cancer is addressing the urgent need for clinical studies that focus on the biological explanations of how drugs work in patients. cancerletter.com/conversation-w…

Amid deepening controversy, Vinay Prasad, FDA’s top clinician and scientist, and director of its Center for Biologics Evaluation and Research, will be leaving the agency.  cancerletter.com/regulatory-new…

Hepatitis B and HIV Cure Consortium receive $24M NIAID grant to find hepatitis B cure (@HopkinsMedicine) cancerletter.com/in-brief/20260…

Guest editorial by Karen E. Knudsen, CEO of @parkerici: "Now more than ever, we need scientists to explore the bold questions that lead to breakthroughs." cancerletter.com/guest-editoria…

Guest editorial by Robert Peter Gale: Poisoning one’s political rivals has a long history. In 399 B.C., an Athenian court found Socrates guilty of “impiety and the corruption of youth” and ordered him to drink a fatal dose of hemlock.  cancerletter.com/cancer-history…

Positive phase III results announced from the SUCCESSOR-2 study of oral mezigdomide in r/r MM (@DanaFarber, @uoaofficial) cancerletter.com/clinical-round…

“We've created a new operating model for collaborative cancer research. We call it radical collaboration, and I think we've delivered on that.” -Tyler Jacks, President of @break_cancer cancerletter.com/conversation-w…

.@PierreFabre and @Atarabio aren’t alone in the predicament of trying to divine what the FDA approval standards are today and what they might be next week.  cancerletter.com/regulatory-new…

Lonny Yarmus named head of the Division of Subspecialty Medicine @MSKCancerCenter cancerletter.com/in-brief/20260…

Phase III persevERA study of giredestrant combination in ER-positive advanced breast cancer does not meet primary objective (@Roche) cancerletter.com/clinical-round…

Guest editorial by Karen E. Knudsen, CEO of @parkerici: "Amidst the uncertainty, one thing is clear: We need a more sustainable, consistent, reliable model to fuel cancer research." cancerletter.com/guest-editoria…

In an email to FDA staff, Commissioner Marty Makary announced the news of Prasad’s departure late Friday, March 6, saying Prasad would conclude his three jobs as CBER director and chief medical and scientific officer at the end of April. cancerletter.com/regulatory-new…

On Jan. 9, Pierre Fabre Pharmaceuticals received a “complete response letter” from FDA: its application for the T-cell therapy tabelecleucel (Ebvallo) was getting a hard No. cancerletter.com/regulatory-new…

Ipsen voluntarily withdraws Tazverik in follicular lymphoma and epithelioid sarcoma cancerletter.com/drugs-and-targ…

Long-term analysis suggests follicular lymphoma can be cured, @fredhutch study finds cancerletter.com/clinical-round…

Five years ago, Tyler Jacks took on a new challenge, becoming president of @break_cancer, a foundation that has pledged to spend at least $500 million to support research projects across top tier cancer centers. cancerletter.com/conversation-w…

Vivek Subbiah to lead Early Drug Development Program at @StanfordCancer cancerletter.com/in-brief/20260…

FDA approves leucovorin for cerebral folate deficiency cancerletter.com/cancer-policy/…

Guest editorial by Robert Peter Gale: "Political assassins used diverse poisons—arsenic, tree bark, dioxin, ricin, polonium-210, and Novichok—to eliminate political rivals." cancerletter.com/cancer-history…

Vinay Prasad, oncology’s gadfly-turned-CBER-director, will leave FDA (again) cancerletter.com/regulatory-new…